Ironshore Pharmaceuticals & Development, Inc. ("Ironshore") has signed an agreement with Restore Health, a company specializing in personalized medicine, to participate in the fulfillment of a double-blind clinical trial, designed to evaluate the safety and efficacy of HLD-200, a new drug in development to treat Attention-deficit/hyperactivity disorder (ADHD). This is Restore's second clinical trial program with Ironshore.
Restore Health originally partnered with Ironshore in 2014 and continues to work with other development-stage companies nationally and internationally. Shara Rudner, RPh., FIACP, FACA, Director, Clinical Trials Group said, "It is an honor to host innovative pharmaceutical and development groups such as Ironshore. We strive to exceed expectations for all clinical trial requirements."
The initial Ironshore trial, completed in 2014, successfully met its primary endpoint, which demonstrated that administration of HLD-200 in the evening improves control of ADHD symptoms in pediatric subjects, as compared to placebo, the following day.
"We are pleased to be partnering with Restore Health for a second time, given their demonstrated ability to manage the complexity of dosing assignments and the logistics of a multi-site trial, and to maintain strict controls according to DEA requirements," said Jill Kapuscinski ,Vice President of Pharmaceutical Operations. "Ironshore is committed to developing a portfolio of products to help improve the quality of life of patients and families that struggle with ADHD."
"Our agreement with Ironshore and continued clinical trial work furthers Restore's mission to accelerate the availability of novel therapies, from 'bench to bedside,' " said Murray I. Firestone, Ph.D., President of Restore Health.